louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06976255: The Effect of Dark Chocolate and Cinnamon Sugars on Pain and Anxiety in University Students With Primary Dysmenorrhea
Official title: The Effect of Dark Chocolate and Cinnamon Sugars on Pain and Anxiety in University Students With Primary Dysmenorrhea: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Primary Dysmenorrhea
Pain
Anxiety
Keywords: university students
dark chocolate
cinnamon sugar
Lead sponsor: Trakya University
Sponsor class: OTHER
Collaborators: name: Bartın Unıversity
First posted: 2025-05-16
Enrollment: 35
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Aim: In this prospective, randomized controlled study, the aim of this study was to investigate the effects of dark chocolate and cinnamon sugar on pain and anxiety in university students with primary dysmenorrhea. Design: The prospective, randomized controlled study


Eligibility criteria: Inclusion Criteria:

* University students who had not given birth,
* Were between the ages of 18 and 25,
* Had regular menstrual cycles (28±7 days),
* Had menstrual pain severity of 5 or more on the Visual Analog Scale (VAS) in the previous month,
* Had primary dysmenorrhea, gave written informed consent,
* Volunteered to participate in the study were included in the study.

Exclusion Criteria:

* The study included patients with hearing loss, pelvic pathology, neurological, endocrine or psychiatric disease, and chronic disease such as diabetes mellitus or heart disease, currently taking medication such as antidepressants or oral contraceptives,
* Menstrual irregularities,
* University students who had mental problems that prevented evaluation and cooperation, obesity, malignant condition, pelvic surgery, pregnancy, analgesic use, chocolate and cinnamon allergy,
* Use of any nutritional supplements, medication or non-drug application (reiki, meditation, reflexology, acupressure, etc.) to reduce pain,
* University students who did not volunteer to participate in the study were excluded.

Primary outcomes:
measure: Visual Analog Scale
timeFrame: change from before implamentation patent and after 1st, 2nd, and 3rd months of practice.]
measure: State-Trait Anxiety Inventory
timeFrame: change from before implamentation patent and after 1st, 2nd, and 3rd months of practice.
Secondary outcomes:
Other outcomes:
Locations:
city: Bartın
country: Turkey
facility: Bartın University
Study officials:
References:
Clinical trial NCT00437255: Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis
Official title: An Evaluation of the Efficacy, Safety, Preference and Duration of Response of Clobex® (Clobetasol Propionate) Spray and Taclonex® (Calcipotriene 0.05%/Betamethasone Dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Plaque Psoriasis
Lead sponsor: Galderma R&D
Sponsor class: INDUSTRY
First posted: 2007-02-19
Enrollment: 122
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.

Detailed description: Same as above.

Eligibility criteria: Inclusion Criteria:

* Moderate to severe psoriasis involving 3-20% of the body surface area

Exclusion Criteria:

* Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® Spray or more than 100 grams per week of Taclonex® Ointment
* Subjects having psoriasis that involves the scalp, face, or groin

Primary outcomes:
measure: Overall Disease Severity
timeFrame: End of treatment (Week 4)
measure: Tolerability assessments, incidence of adverse events
timeFrame: Baseline, Weeks 1, 2, 4 and 8
Secondary outcomes:
measure: Overall Disease Severity
timeFrame: Weeks 1, 2 and 8
measure: Investigator Global Assessment
timeFrame: End of treatment (week 4) and Weeks 1, 2 and 8
Other outcomes:
Locations:
city: Fridley
country: United States
facility: Minnesota Clinical Study Center
state: Minnesota
city: Austin
country: United States
facility: DermResearch, Inc.
state: Texas
city: Bryan
country: United States
facility: J & S Studies, Inc.
state: Texas
city: Dallas
country: United States
facility: Baylor Research Institute
state: Texas
Study officials:
affiliation: Galderma Laboratories, LP
name: Ronald W Gottschalk, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04949555: Long Term Evaluation of Primary Congenital Glaucoma Management in Sohag University Hospital
Official title: Long Term Evaluation of Primary Congenital Glaucoma Management In Sohag University Hospital
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Primary Congenital Glaucoma
Keywords: primary congenital glaucoma
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2021-07-02
Enrollment: 150
Sex: ALL
Minimum age (years): 3
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patient s with primary congenital glaucoma operated in sohag university hospital

Brief summary: evaluation of primary congenital glaucoma management in sohag university hospital

Detailed description: long term evaluation of primary congenital glaucoma management in sohag university hospital

Eligibility criteria: Inclusion Criteria:

* children operated more than 3 months

Exclusion Criteria:

* other types of operated pediatric glaucoma

Primary outcomes:
measure: evaluation of patient with primary congenital glaucoma managed in sohag university hospital by surgical intervention,trabeculectomy and trabecultomy with mitomycin and ologen.follow up after management by measuring intra ocular pressure by Perkins.
timeFrame: 3years
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Ghada Fathy Mohamed
Study officials:
affiliation: Sohag University
name: ghada f mohamed, MBBCH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06856655: Achieving Portal Access With Scorpion Post-Approval Study 2
Official title: A Retrospective Data Collection Evaluating Portal Vein Access Sets For Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedures
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Portal Hypertension
Liver Diseases
Ascites Hepatic
Hydrothorax
Vascular Diseases
Keywords: Transjugular Intrahepatic Portosystemic Shunt
TIPS
Portal Vein Access
Lead sponsor: Argon Medical Devices
Sponsor class: INDUSTRY
First posted: 2025-03-04
Enrollment: 82
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The procedure date window for the retrospective data was from 01-Feb-2022 to 05-Feb-2024.

Brief summary: Creation of the parenchymal tract between the portal vein and the hepatic vein is the most difficult and time consuming step in a TIPS procedure. The purpose of this study is to evaluate portal vein access sets during the TIPS procedure.


Eligibility criteria: Inclusion Criteria:

1. Scorpion or Scorpion X kit introduced into the vasculature as the initial device for portal vein access

Exclusion Criteria:

1. TIPS procedure was not initiated and/or no portion of the kit was introduced into the vasculature
2. Inaccessible medical records

Primary outcomes:
measure: Number of Participants With Technical Success
timeFrame: TIPS Procedure
measure: Composite of Major Complications
timeFrame: Through 30 days post-TIPS procedure
Secondary outcomes:
measure: Number of Participants with Procedural Success
timeFrame: TIPS Procedure
measure: Device-Related Complications
timeFrame: Through 30 days post-TIPS procedure
Other outcomes:
measure: Portal Vein Access (PVA) Time
timeFrame: TIPS Procedure
measure: Procedure duration
timeFrame: TIPS Procedure
measure: Fluoroscopy Time
timeFrame: TIPS Procedure
measure: Change in MELD score
timeFrame: up to 30 days post-TIPs procedure
measure: Change in Child-Pugh score
timeFrame: up to 30 days post-TIPs procedure
Locations:
city: Atlanta
country: United States
facility: Emory University
state: Georgia
Study officials:
References:
Clinical trial NCT00569855: Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery
Official title: Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Open-heart Surgery
Cardiopulmonary Bypass
Lead sponsor: University of Arkansas
Sponsor class: OTHER
Collaborators: name: Arkansas Children's Hospital Research Institute
First posted: 2007-12-10
Enrollment: 785
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Cardiopulmonary bypass is done with a machine that does the work of the heart and lungs during open-heart surgery. This study is to determine if intravenous (i.v.) phenoxybenzamine is safe. This drug lowers the blood pressure, making it easier for the cardiopulmonary bypass machine to deliver blood and oxygen to all of the organs and tissues.


Eligibility criteria: Inclusion Criteria:

* 0-18 years of age
* weight of less than or equal to 20 kilograms

Exclusion Criteria:

* Parental refusal to give informed consent

Primary outcomes:
measure: Number of Participants Who Had Significant Hypotension as Defined in the Protocol as Need for Norepinephrine Dose >0.1mcq/kg/Min in the First 72 Hours Postoperatively
timeFrame: 72 hours postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Arkansas Children's Hospital
state: Arkansas
Study officials:
affiliation: Arkansas Childrens Hospital
name: Michiaki Imamura, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05374655: Outcomes Study of Glycosylated Hemoglobin Control in Cox-Maze IV During Cardiac Surgery
Official title: A Multicenter Randomized Controlled Clinical Study of Preoperative Glycosylated Hemoglobin Control Strategies on the Effectiveness of Cox-Maze IV Procedure for Atrial Fibrillation During Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cardiac Surgery
Keywords: Cardiac Surgery
Atrial Fibrillation
Glycosylated Hemoglobin
Cox-Maze IV
Lead sponsor: Beijing Anzhen Hospital
Sponsor class: OTHER
Collaborators: name: Peking University People's Hospital
name: Peking University International Hospital
name: Beijing Huaxin Hospital
First posted: 2022-05-16
Enrollment: 148
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: In recent years, a growing body of research has shown that diabetes plays an important role in the development and recurrence of atrial fibrillation. How to achieve the treatment and prevention of recurrence of atrial fibrillation through appropriate blood glucose control is the current focus of clinical research. Glycosylated hemoglobin (HbA1c) is the product of a non-enzymatic reaction in which hemoglobin in red blood cells is combined with sugars in the serum (mainly glucose). The purpose of this multicenter, randomized controlled study is to compare the effects of different glycosylated hemoglobin control strategies on the effectiveness of Cox-Maze IV procedure for atrial fibrillation during cardiac surgery.


Eligibility criteria: Inclusion Criteria:

* Age ≥18 years
* Elective cardiac surgery
* A clear diagnosis of diabetes mellitus, and HbA1c ≥ 7.5% at the time of initial diagnosis and treatment
* Preoperative combination of persistent or long-term persistent atrial fibrillation

Exclusion Criteria:

* Emergency surgery or limited-term surgery
* Previous cardiac surgery
* Left atrial diameter \> 65 mm
* Serum creatine \> 1.8 mg/dL
* Previous severe liver disease
* Pregnant or planning to become pregnant
* Have a malignant tumor

Primary outcomes:
measure: Rate of atrial fibrillation recurrence
timeFrame: one year post operative
Secondary outcomes:
measure: Rate of atrial fibrillation recurrence
timeFrame: 6 months post operative
measure: All-cause Mortality
timeFrame: one year post operative
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Anzhen Hospital
Study officials:
affiliation: Beijing Anzhen Hospital
name: Kun Hua
role: STUDY_CHAIR
References:
Clinical trial NCT03137355: The International Registry for Leigh Syndrome
Official title: The International Registry for Leigh Syndrome
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Leigh Syndrome
Leigh Disease
Leigh's Necrotizing Encephalopathy
Subacute Necrotizing Encephalomyopathy
Subacute Necrotizing Encephalomyelopathy
Keywords: Leigh Syndrome
Leigh Disease
Leigh's Necrotizing Encephalopathy
Subacute Necrotizing Encephalomyelopathy
Subacute Necrotizing Encephalomyopathy
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
First posted: 2017-05-02
Enrollment: 200
Sex: ALL
Minimum age (years): 0
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People with a diagnosis of Leigh syndrome.

Brief summary: The purpose of this study is to develop a database containing clinical and laboratory information for patients with Leigh syndrome. The goal is to provide a greater understanding of Leigh syndrome allowing further characterization of this disease.

Detailed description: Leigh syndrome, also known as juvenile sub-acute necrotizing encephalopathy, is a progressive neurodegenerative disorder associated with dysfunction of mitochondrial oxidative phosphorylation (OXPHOS). First described in 1951 by British neuropsychiatrist Archibald Denis Leigh, the condition has evolved from a post mortem diagnosis to a clinical entity with characteristic radiologic and laboratory findings.

Leigh syndrome is a rare and heterogeneous disease, finding a substantial number of patients to study is difficult. The lack of natural history data in Leigh syndrome and the small number of patients included in clinical reports thus far has limited the ability to fully comprehend the progression of this disease and assess prognostic factors. A Leigh syndrome database will help improve our understanding of this rare disease leading to an improved ability to predict outcomes and/or improve treatment paradigms. Collecting natural history data on Leigh syndrome and integrating this information into a database will be useful in understanding the course of the disease and identifying trends.

Eligibility criteria: Inclusion Criteria:

* All participants with a diagnosis of Leigh syndrome will be invited to participate

Exclusion Criteria:

* People without Leigh syndrome

Primary outcomes:
measure: Phenotypical characteristics of Leigh syndrome
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: The University of Texas Health Science Center at Houston
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center, Houston
name: Mary Kay Koenig, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02044055: Mother-to-child Hepatitis D Transmission
Official title: Hepatitis D Virus (HDV) Mother-To-Child Transmission (MTCT) From Hepatitis B Virus (HBV)-Hepatitis D Virus (HDV) Co-infected Pregnant Women: a Retrospective Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatitis D
Transmission
Lead sponsor: Hopital Lariboisière
Sponsor class: OTHER
First posted: 2014-01-23
Enrollment: 54
Sex: ALL
Minimum age (years): 9
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All children born in the Maternity Department, Lariboisiere Hospital, from HBV-HDV co-infected women

Brief summary: HBV can be transmitted from mother-to-child, with a risk increasing according to maternal HBV DNA during pregnancy. HDV is a defective virus using HBs Ag for its own replication. Nucleosides analogues have only a minor impact on quantitative HBs Ag level. Data about vertical HDV transmission are old, justifying a new study.

Detailed description: Hepatitis B Virus (HBV) can be transmitted from mother-to-child, with a risk increasing according to maternal HBV DNA viral load during the last trimester of pregnancy. Nucleosides analogues, lamivudine, telbivudine, or nucleotides analogues, tenofovir DF decrease HBV mother-to-child transmission risk, and are recommended in Guidelines (EASL 2012) for pregnant women with HBV DNA above 1,000 000 I.U/mL. HDV is a defective virus using HBs Ag for its own replication. HDV-HBV co-infection is a re-emerging infectious disease in western countries, due to immigration of people coming from endemic areas. Nucleosides analogues have only a minor impact on quantitative HBs Ag level (Boyd A et al. AIDS Research and Human Retroviruses 2013). Data about vertical HDV transmission are old (Rizzetto, et al. J Med Virol 1982), before a large use of nucleosides/nucleotides analogues in HBV infected pregnant women, justifying a new study.

Eligibility criteria: Inclusion Criteria:

* children born in the Maternity Department, Lariboisiere Hospital,
* from HBV-HDV co-infected women
* with a positive HDV RNA during pregnancy in the pregnant woman

Exclusion Criteria:

* negative HDV RNA during pregnancy in the pregnant woman

Primary outcomes:
measure: Hepatitis D antibodies (Ab) in children
timeFrame: up to 10 years (expected average: 5 years)
Secondary outcomes:
measure: HDV RNA in children with positive HDV Ab
timeFrame: up to 10 years (expected average: 5 years)
Other outcomes:
Locations:
city: Paris
country: France
facility: Hopital Lariboisiere
Study officials:
affiliation: Hopital Lariboisiere
name: Pierre O SELLIER, M.D., Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sellier PO, Maylin S, Brichler S, Bercot B, Lopes A, Chopin D, Pogliaghi M, Munier AL, Delcey V, Simoneau G, Evans J, Gordien E, Simon F, Bergmann JF. Hepatitis B Virus-Hepatitis D Virus mother-to-child co-transmission: A retrospective study in a developed country. Liver Int. 2018 Apr;38(4):611-618. doi: 10.1111/liv.13556. Epub 2017 Sep 12.
Clinical trial NCT03459755: Evaluating Race Specific AGE Accumulation As a Behavioral Biomarker Prostate Cancer Survivors
Official title: Evaluating Race Specific AGE Accumulation As a Behavioral Biomarker That Can Reflect Optimal Health in Prostate Cancer Survivors
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Prostate Cancer
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
First posted: 2018-03-09
Enrollment: 0
Sex: MALE
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to show that reduction in advanced glycation end-products (AGEs) is associated with the beneficial regulation of receptor for AGE (RAGE) mediated tumor response which may correlate with improved quality of life in PCa survivors. AGEs are produced by the body and are affected by lifestyle, weight and diet.


Eligibility criteria: Inclusion Criteria:

1. Patient diagnosed with non-metastatic Stage I-III Prostate Cancer
2. Age 45 years and older
3. Within 12 months of first histologic prostate cancer diagnosis.
4. Completed planned chemotherapy and/or radiation therapy 4 weeks or more prior to study.
5. BMI \> 25
6. ECOG Performance Status 0 or 1.
7. Access to a telephone.
8. Able to read and understand written and spoken English.
9. Participants must be accessible for treatment and follow-up and must sign informed consent.
10. Subjects with known diabetes are permitted. However, they must be under active treatment for this condition.
11. Participants must past the cardiac rehabilitation center stress test.

Exclusion Criteria:

1. Planned enrollment in other formalized physical activity or diet counseling program during the 12 weeks of study
2. Received chemotherapy or radiation therapy within 4 weeks of enrollment
3. Had previous weight loss surgery (e.g. gastric bypass, sleeve gastrectomy and biliary pancreatic diversion).
4. Previously participated in Cardiac-Rehab
5. Have constrained mobility secondary to problems with balance, bone and/or joint disease
6. Have unstable angina or cardiovascular disease that prohibits exercise.

Primary outcomes:
measure: Compare RAGE response (measured in the blood) to changes in Quality of Life using the EORTC QLQ-30 questionnaire.
timeFrame: From baseline to up to 52 weeks
measure: Compare RAGE response (measured in the blood) to changes in Quality of Life using the CES-D questionnaire.
timeFrame: From baseline to up to 52 weeks
Secondary outcomes:
measure: Effect of Lifestyle intervention (physical activity and diet) on AGE levels measured in the blood
timeFrame: From baseline up to 52 weeks
Other outcomes:
Locations:
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
Study officials:
affiliation: Medical University of South Carolina
name: David Turner, PhD
role: PRINCIPAL_INVESTIGATOR
References: